ArticleCancer2015
Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma.
Article in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Guideline
- General health versus tumor stage: determinants of survival in Merkel cell carcinoma assessed by sentinel lymph node biopsy.Journal of cancer research and clinical oncology · 2026Article
- Anatomical lymphatic drainage basin and sentinel lymph node positivity in Merkel cell carcinoma: a 37-year single-center cohort study of 400 patients.Frontiers in oncology · 2026Article
- ASO Author Reflections: Merkel Cell Carcinoma and Nodal Staging with SLNB.Annals of surgical oncology · 2026Article
- Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy.Annals of surgical oncology · 2026Article
- Prognostic value of different immunohistopathological patterns and Ki67 proliferation index for Merkel cell carcinoma.Head & face medicine · 2025Article
- Optimizing radiation therapy for merkel cell carcinoma: evaluating prognostic factors and treatment outcomes.International journal of clinical oncology · 2025Article
- The prognostic role of PD-L1 expression and the presence of polyomavirus in Merkel cell carcinoma cases.Infectious agents and cancer · 2024Article
- Review
- Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status.Brain sciences · 2023Article
- Review
- An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma.Annals of surgical oncology · 2022Article
- Predictors of Nodal Metastasis in Cutaneous Head and Neck Cancers.Current oncology reports · 2022Review
- The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis.Clinical & experimental metastasis · 2022Review
- Article
- Merkel Cell Carcinoma: New Trends.Cancers · 2021Review
- Patterns of Metastasis in Merkel Cell Carcinoma.Annals of surgical oncology · 2021Article
- Evidence and Considerations on Treatment of Small Size Merkel Cell Head and Neck Carcinoma.International archives of otorhinolaryngology · 2020Article
- Article
- The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.Nature reviews. Clinical oncology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
backgroundThe purposes of this study were 1) to determine the impact of primary tumor-related factors on the prediction of the sentinel lymph node (SLN) status and 2) to identify clinical and pathologic factors associated with survival in Merkel cell carcinoma (MCC).
methodsAn institutional review board-approved, retrospective review of patients with MCC treated between 1988 and 2011 at a single center was performed. Patients were categorized into 5 groups: 1) negative SLN, 2) positive SLN, 3) clinically node-negative but SLN biopsy not performed, 4) regional nodal disease without a known primary tumor, and 5) primary MCC with synchronous clinically evident regional nodal disease. Factors predictive of the SLN status were analyzed with logistic regressions, and overall survival (OS) and disease-specific survival (DSS) were analyzed with Cox models and competing risk models assuming proportional hazards, respectively.
resultsThree hundred seventy-five patients were analyzed, and 70% were male; the median age was 75 years. The median tumor diameter was 1.5 cm (range, 0.2-12.5 cm), and the median tumor depth was 4.8 mm (range, 0.3-45.0 mm). One hundred ninety-one patients underwent SLN biopsy, and 59 (31%) were SLN-positive. Increasing primary tumor diameter and increasing tumor depth were associated with SLN positivity (P = .007 and P = .017, respectively). Age and sex were not associated with the SLN status. Immunosuppression, increasing tumor diameter, and increasing tumor depth were associated with worse OS (P = .007, P = .003, and P = .025, respectively). DSS differed significantly by group and was best for patients with a negative SLN and worst for those with primary MCC and synchronous clinically evident nodal disease (P = .018).
conclusionFor patients with MCC, increasing primary tumor diameter and increasing tumor depth are independently predictive of a positive SLN, worse OS, and worse DSS. Tumor depth should be routinely reported when primary MCC specimens are being evaluated histopathologically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.